Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase I Study of the Wee 1 Kinase (Wee 1) Inhibitor AZD1775 in Combination With Radiotherapy and Cisplatin in Cervical, Upper Vaginal, and Uterine Cancers (10041848, 10008224, 10008238, 10046888, 10014735)

Trial Profile

A Phase I Study of the Wee 1 Kinase (Wee 1) Inhibitor AZD1775 in Combination With Radiotherapy and Cisplatin in Cervical, Upper Vaginal, and Uterine Cancers (10041848, 10008224, 10008238, 10046888, 10014735)

Recruiting
Phase of Trial: Phase I

Latest Information Update: 07 Oct 2018

At a glance

  • Drugs Adavosertib (Primary) ; Cisplatin
  • Indications Adenocarcinoma; Cervical cancer; Uterine cancer
  • Focus Adverse reactions
  • Most Recent Events

    • 31 Aug 2018 Biomarkers information updated
    • 26 Apr 2018 Planned number of patients changed from 24 to 33.
    • 21 Nov 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top